guest ::
| Home > Publications Database > Effects of methylphenidate on the behavior of male 5xFAD mice. > print |
| Home > Publications Database > Effects of methylphenidate on the behavior of male 5xFAD mice. > print |
| 001 | 137747 | ||
| 005 | 20240321220315.0 | ||
| 024 | 7 | _ | |a 10.1016/j.pbb.2014.11.006 |2 doi |
| 024 | 7 | _ | |a pmid:25449360 |2 pmid |
| 024 | 7 | _ | |a 0091-3057 |2 ISSN |
| 024 | 7 | _ | |a 1873-5177 |2 ISSN |
| 024 | 7 | _ | |a altmetric:4522453 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-04069 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Schneider, F. |0 P:(DE-2719)2810406 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Effects of methylphenidate on the behavior of male 5xFAD mice. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2015 |b Elsevier Science |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2015-01-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705937368_13657 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Alzheimer's disease is a neurodegenerative disorder characterized by a loss of memory and spatial orientation. It is also reported that the dopamine system is affected. Dopamine plays a prominent role in motor functions, motivation, emotion, arousal and reward, and it is important for learning and memory. One model that represents characteristic hallmarks of Alzheimer's disease is the 5xFAD mouse model, in which parenchymal plaque load starts at 2months of age. Transgenic 5xFAD mice show the first behavioral deficits at 6months, which are evident at 9months of age. In this study, we investigated the pharmacological influence of methylphenidate (MPH) on behavioral deficits of 5xFAD mice. Using a battery of behavioral tests, we observed no influence of MPH on anxiety in the elevated plus maze, whereas the locomotion and explorative activity in the open field was increased in transgenic and non-transgenic 5xFAD mice after the application of MPH. Further MPH inhibits habituation in the open field in healthy 5xFAD littermates after the application of 10mg/kg MPH. On the other hand, 10mg/kg MPH improved spatial memory in 6-month-old transgenic 5xFAD males, i.e., at a time point when deficits start to occur. However, in 9-month-old transgenic mice, MPH did not improve persisting learning and memory deficits. We concluded that MPH might improve the non-cognitive, apathy-like behavior (indicated by a reduced exploration), but it has no influence on sustained Alzheimer typical learning and memory deficits. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2015-01-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Amyloid beta-Protein Precursor |2 NLM Chemicals |
| 650 | _ | 7 | |a Central Nervous System Stimulants |2 NLM Chemicals |
| 650 | _ | 7 | |a Mutant Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a PSEN1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Presenilin-1 |2 NLM Chemicals |
| 650 | _ | 7 | |a Methylphenidate |0 207ZZ9QZ49 |2 NLM Chemicals |
| 650 | _ | 2 | |a Alzheimer Disease: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: psychology |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Protein Precursor: genetics |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Anxiety: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Behavior, Animal: drug effects |2 MeSH |
| 650 | _ | 2 | |a Behavior, Animal: physiology |2 MeSH |
| 650 | _ | 2 | |a Central Nervous System Stimulants: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 650 | _ | 2 | |a Exploratory Behavior: drug effects |2 MeSH |
| 650 | _ | 2 | |a Habituation, Psychophysiologic: drug effects |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Maze Learning: drug effects |2 MeSH |
| 650 | _ | 2 | |a Methylphenidate: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Mice, Transgenic |2 MeSH |
| 650 | _ | 2 | |a Motor Activity: drug effects |2 MeSH |
| 650 | _ | 2 | |a Mutant Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Presenilin-1: genetics |2 MeSH |
| 700 | 1 | _ | |a Baldauf, K. |0 P:(DE-2719)2239681 |b 1 |e Corresponding author |u dzne |
| 700 | 1 | _ | |a Wetzel, W. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Reymann, Klaus |0 P:(DE-2719)2740485 |b 3 |e Last author |u dzne |
| 773 | 1 | 8 | |a 10.1016/j.pbb.2014.11.006 |b : Elsevier BV, 2015-01-01 |p 68-77 |3 journal-article |2 Crossref |t Pharmacology Biochemistry and Behavior |v 128 |y 2015 |x 0091-3057 |
| 773 | _ | _ | |a 10.1016/j.pbb.2014.11.006 |g Vol. 128, p. 68 - 77 |0 PERI:(DE-600)2008734-2 |q 128<68 - 77 |p 68-77 |t Pharmacology, biochemistry and behavior |v 128 |y 2015 |x 0091-3057 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/137747/files/DZNE-2020-04069_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/137747/files/DZNE-2020-04069_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:137747 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2810406 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2239681 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2740485 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PHARMACOL BIOCHEM BE : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-2719)1310005 |k AG Reymann |l Pathophysiology of Dementia |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1340016 |k Core MR PET |l Core MR PET |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1310005 |
| 980 | _ | _ | |a I:(DE-2719)1340016 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|